Mouse anti Human CD13 conjugated with FITC
| Code | Size | Price |
|---|
| EXA-0132 | 100 Tests | £221.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: E735
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Shipping:
Room Temperature
Storage:
Product should be stored at 4-8°C. DO NOT FREEZE
Further Information
Applications Description:
PBMC: Add10 ?l of MAB/10^6 PBMC in 100 ?l PBS. Mix gently and incubate for 15 minutes at 2? to 8?C. Wash twice with PBS and analyze. WHOLE BLOOD: Add 10 ?l of MAB/100 ?l of whole blood. Mix gently and incubate for 15 minutes at room temperature (20?C). Lyse the whole blood. Wash once with PBS and analyze. See instrument manufacturer?s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
Background:
Identification of human Monocytes and Granulocytes expressing the 150 kD M.W. surface antigen. CD13 is a membrane enzyme, Aminopeptidase N. Myeloid cells in regenerating bone marrow will have an increased expression of CD13 in comparison with normal bone marrow myeloid cells.
Caution:
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
Concentration:
Titered for flow cytometry
Field of Interest:
Flow Cytometry
Formulation:
Provided as sterile filtered solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein
Functional Analysis:
Flow Cytometry Staining
Immunogen:
CD13=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c x C57BL16 hybrid mice immunized with KG-1a cell line.
Product Form:
FITC
Product Stability:
Reagents are stable for the period shown on the vial label when stored properly
Purification Method:
Protein A/G Chromatography
Synonyms:
CD13 FITC
UniProt:
P15144
References
1. Induction of CD13 expression on fresh myeloid leukemia: correlation of CD13 expression with aminopeptidase-N activity. Razak K; Newland AC Leuk Res 1992 Jun-Jul;16(6-7):625-30.
2. Surface marker expression in acute myeloid leukemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D Br J Haematol 1992 May;81(1):40-4.
3. Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Bassan R; Biondi A; Benvestito S; Tini ML; Abbate M; Viero P; Barbui T; Rambaldi A Cancer 1992 Jan 15;69(2):396-404.
4. Monocytes appearing repeatedly after chemotherapies had an identical rearrangement pattern of immunoglobulin with leukemic blasts in a patient with CD13+ acute lymphoblastic leukemia. Mizuki M; Tagawa S; Nojima J; Nakamura Y; Morita T; Yumura-Yagi K; Hara J; Kawa-Ha K; Kitani T Acta Haematol 1992;87(1-2):88-93.
2. Surface marker expression in acute myeloid leukemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D Br J Haematol 1992 May;81(1):40-4.
3. Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Bassan R; Biondi A; Benvestito S; Tini ML; Abbate M; Viero P; Barbui T; Rambaldi A Cancer 1992 Jan 15;69(2):396-404.
4. Monocytes appearing repeatedly after chemotherapies had an identical rearrangement pattern of immunoglobulin with leukemic blasts in a patient with CD13+ acute lymphoblastic leukemia. Mizuki M; Tagawa S; Nojima J; Nakamura Y; Morita T; Yumura-Yagi K; Hara J; Kawa-Ha K; Kitani T Acta Haematol 1992;87(1-2):88-93.